How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

2,906 results for

Growth Delay Onset Determination

by
...
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1. Growth Delay Onset Determination

Growth Delay Onset Determination Growth Delay Onset Determination Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 Growth Delay Onset (...) Determination Growth Delay Onset Determination Aka: Growth Delay Onset Determination From Related Chapters II. Causes: Intrauterine Growth Retardation tic or chromosomal abnormality Transplacental infectious disease ( ) Toxins Nicotine Medications III. Causes: Birth Prolonged Panhypopituitarism IV. Causes: Childhood See Images: Related links to external sites (from Bing) These images are a random sampling from a Bing search on the term "Growth Delay Onset Determination." Click on the image (or right click

2018 FP Notebook

2. COMBOPROFEN for Treatment of Muscular Pain Associated With Delayed Onset Muscle Soreness (DOMS)

COMBOPROFEN for Treatment of Muscular Pain Associated With Delayed Onset Muscle Soreness (DOMS) COMBOPROFEN for Treatment of Muscular Pain Associated With Delayed Onset Muscle Soreness (DOMS) - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one (...) or more studies before adding more. COMBOPROFEN for Treatment of Muscular Pain Associated With Delayed Onset Muscle Soreness (DOMS) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT03223519 Recruitment Status : Completed First Posted : July 21, 2017 Last Update Posted : January 23, 2018 Sponsor

2017 Clinical Trials

3. Growth Delay Onset Determination

Growth Delay Onset Determination Growth Delay Onset Determination Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 Growth Delay Onset (...) Determination Growth Delay Onset Determination Aka: Growth Delay Onset Determination From Related Chapters II. Causes: Intrauterine Growth Retardation tic or chromosomal abnormality Transplacental infectious disease ( ) Toxins Nicotine Medications III. Causes: Birth Prolonged Panhypopituitarism IV. Causes: Childhood See Images: Related links to external sites (from Bing) These images are a random sampling from a Bing search on the term "Growth Delay Onset Determination." Click on the image (or right click

2015 FP Notebook

4. Management of Neonates Born at ?34 6/7 Weeks’ Gestation With Suspected or Proven Early-Onset Bacterial Sepsis

, and two-thirds of preterm births are associated with preterm labor, PROM, or clinical concern for intrauterine infection, risk stratification strategies cannot be applied to preterm infants in the same manner as for term neonates. In particular, the Neonatal Early-Onset Sepsis Risk Calculator does not apply to infants born before 34 0/7 weeks’ gestation. The objective of EOS risk assessment among preterm infants is, therefore, to determine which infants are at the lowest risk for infection and who (...) . , The use of 2 separate bottles may provide the opportunity to determine if commensal species are true infections by comparing growth in the two. , Use of 1 aerobic and 1 anaerobic culture bottle may optimize organism recovery. Most neonatal pathogens, including GBS, E coli , coagulase-negative Staphylococcus , and Staphylococcus aureus , will grow in anaerobic conditions. One study revealed that with routine use of both pediatric aerobic and adult anaerobic blood cultures, strict anaerobic species

2018 American Academy of Pediatrics

5. Delayed Umbilical Cord Clamping After Birth

with the neonatal care provider is essential. The ability to provide delayed umbilical cord clamping may vary among institutions and settings; decisions in those circumstances are best made by the team caring for the mother–infant dyad. There are several situations in which data are limited and decisions regarding timing of umbilical cord clamping should be individualized (Table 1). For example, in cases of fetal growth restriction with abnormal umbilical artery Doppler studies or other situations in which (...) outcomes, delayed umbilical cord clamping does not increase the risk of postpartum hemorrhage or the need for blood transfusion. Additionally, postpartum maternal hemoglobin levels are not affected by delayed compared with immediate umbilical cord clamping. References Yao AC, Moinian M, Lind J. Distribution of blood between infant and placenta after birth. Lancet 1969;2:871–3. [ ] Linderkamp O. Placental transfusion: determinants and effects. Clin Perinatol 1982;9:559–92. [ ] Philip AG, Saigal S. When

2017 American College of Obstetricians and Gynecologists

6. Loss of Akt1 or Akt2 delays mammary tumor onset and suppresses tumor growth rate in MTB-IGFIR transgenic mice. (PubMed)

Loss of Akt1 or Akt2 delays mammary tumor onset and suppresses tumor growth rate in MTB-IGFIR transgenic mice. Akt is a serine/threonine kinase that mediates signaling downstream of tyrosine kinase receptors like the type I insulin-like growth factor receptor (IGF-IR). In fact, we have previously shown that mammary tumors induced by elevated expression of the IGF-IR are associated with hyperactivation of Akt. However, there are three mammalian isoforms of Akt (Akt1, Akt2 and Akt3 (...) ) and these isoforms regulate distinct physiologic properties within cells. In this manuscript, the impact of disrupting Akt1 or Akt2 in mammary tumors induced by IGF-IR overexpression were examined to determine whether specific Akt isoforms regulate different aspects of mammary tumorigenesis.Akt1 and Akt2 levels were stably ablated in mammary tumors of MTB-IGFIR transgenic mice by crossing MTB-IGFIR transgenic mice with either Akt1(-/-) or Akt2(-/-) mice. Tumor onset, growth rate, and metastasis were

Full Text available with Trip Pro

2013 BMC Cancer

7. Developmental rheumatology in children. Scenario: Delayed walking in children

with in-toeing for specialist assessment, using clinical judgement to determine the urgency, if any of the following are present: A feature. Sudden onset of in-toeing. Associated pain. Extreme or persistent changes. Unilateral or asymmetric intoeing. Limp, daily recurrent trips or falls, or functional problems. Delayed developmental milestones. Significant history for an underlying metabolic, neuromuscular, or orthopaedic reason for in-toeing. Abnormal examination findings (for example rigid foot, asymmetric (...) in the community (for example by a podiatrist with paediatric expertise) is usually appropriate for a child with heel pain if all of the following are present: The child is well and there are no features. Milestones are normal with no delay or regression. There is no limp or interference with daily activities. Consider referring children with heel pain for specialist assessment, using clinical judgement to determine the urgency, if any of the following are present: features. Visible swelling or abnormality

2019 NICE Clinical Knowledge Summaries

8. Association between the onset age of puberty and parental height. (PubMed)

"). We hypothesized that the variability of the onset age of puberty contributes to the attainment of a final height which is similar to the target height. We hypothesized that whenever a child's height-percentile differs from the target height percentile (we called this difference the "height gap"), the onset of puberty is advanced or delayed so that they are closer or even equal at the end of pubertal growth. The association between height gap and onset age of puberty was investigated (...) in the reported study.The study is an observational retrospective study on growth during puberty in 170 Israeli (60 girls) and 335 Polish children (162 girls). Anthropometric measurements were analyzed by multivariable linear regression with the onset age of the pubertal growth spurt (PGS) as the dependent variable, and two independent variables "height gap" and body mass index (BMI)-both standardized.The adjusted coefficient of determination (adj R2) between the onset age of the PGS and the two independent

2019 PLoS ONE

9. Fingolimod enhances the efficacy of delayed alteplase administration in acute ischemic stroke by promoting anterograde reperfusion and retrograde collateral flow

Fingolimod enhances the efficacy of delayed alteplase administration in acute ischemic stroke by promoting anterograde reperfusion and retrograde collateral flow The present study was undertaken to determine the efficacy of coadministration of fingolimod with alteplase in acute ischemic stroke patients in a delayed time window.This was a prospective, randomized, open-label, blinded endpoint clinical trial, enrolling patients with internal carotid artery or middle cerebral artery proximal (...) occlusion within 4.5 to 6 hours from symptom onset. Patients were randomly assigned to receive alteplase alone or alteplase with fingolimod. All patients underwent pretreatment and 24-hour noncontrast computed tomography (CT)/perfusion CT/CT angiography. The coprimary endpoints were the decrease of National Institutes of Health Stroke Scale scores over 24 hours and the favorable shift of modified Rankin Scale score (mRS) distribution at day 90. Exploratory outcomes included vessel recanalization

Full Text available with Trip Pro

2018 EvidenceUpdates

10. Hypothalamic - Pituitary and Growth Disorders in Survivors of Childhood Cancer

hypothalamic–pituitary axis radiation. (1∣⊕⊕OO) 2.5 We suggest against using spontaneous growth hormone secretion ( e.g. , 12-hour overnight sampling) as a diagnostic test in determining GH deficiency in childhood cancer survivors. (2∣⊕OOO) 2.6 We recommend that formal testing to establish a diagnosis of growth hormone deficiency is not required in childhood cancer survivors with three other confirmed anterior pituitary hormone deficits. (1∣⊕⊕OO) 2.7 We recommend retesting adult cancer survivors exposed (...) for impaired growth and short stature in cancer survivors are CRT, CSI, TBI, and younger age at the time of treatment ( ). Exposure to 18 to 30 Gy CRT may result in GHD and precocious puberty, whereas doses >30 Gy may result in multiple pituitary hormone deficiencies ( , ). Exposure to CRT can also result in an earlier onset or altered tempo of puberty, including onset of breast development between ages 8 and 9 years, peak height velocity at age ≤10 years, and early menarche ( ). Importantly, children who

Full Text available with Trip Pro

2018 The Endocrine Society

11. Cost-Conscious Growth-Promoting Treatment: When Discretion Is the Better Part of Value

degree of disordered growth can in- terfere with day-to-day living to a degree that its treat- ment lies appropriately within the realm of medicine. The likely prospect for an adult height clearly below the statistical population normal range (e.g., < 1st percentile) might be a height threshold for diminished opportunity justifying consideration of hGH treatment on which most could agree. Beyond that, however, determining whether there is value (i.e., improved psychosocial out- come) in hGH treatment (...) of long-term growth hormone treatment of idiopathic short stature. J Clin Endocrinol Metab. 2005 Sep; 90(9): 5247–53. 26 Salehpour S, Alipour P, Razzaghy-Azar M, Ardeshirpour L, Shamshiri A, Monfared MF, et al. A double-blind, placebo-controlled comparison of letrozole to oxandrolone ef- fects upon growth and puberty of children with constitutional delay of puberty and idio- pathic short stature. Horm Res Paediatr. 2010; 74(6): 428–35. 27 Schroor EJ, van Weissenbruch MM, Knibbe P, Delemarre-van de

2018 Pediatric Endocrine Society

12. Asfotase alfa for treating paediatric-onset hypophosphatasia

50–100% of babies die within the first year of life, primarily because of respiratory failure. Juvenile-onset hypophosphatasia that develops later in childhood is associated with a substantially lower mortality rate than the form that appears in infancy, but is often debilitating and leads to bone deformities that may result in delayed walking, limb weaknesses, skeletal pain and non-traumatic fractures. 2.3 The prevalence of severe forms of hypophosphatasia is unknown in England. However (...) medical records of children up to 5 years. ALX-HPP-502, a retrospective natural history study of children with juvenile-onset hypophosphatasia (5–15 years). The study focused on functional assessments of physical abilities, changes in growth (height and weight) and skeletal improvement (severity of rickets). ALX-HPP-502s, a single-centre substudy of ALX-HPP-502. Data for additional functional measures were taken from medical records and videos were obtained from a longitudinal natural history database

2017 National Institute for Health and Clinical Excellence - Highly specialised technology

13. Persistent Target Mismatch Profile &gt;24 Hours After Stroke Onset in DEFUSE 3. (PubMed)

at presentation, may experience delayed infarct expansion, and have poor clinical outcomes. Clinical trials are needed to determine if patients with a favorable perfusion profile benefit from reperfusion beyond 24 hours. Clinical Trial Registration- URL: https://www.clinicaltrials.gov . Unique identifier: NCT02586415. (...) Persistent Target Mismatch Profile >24 Hours After Stroke Onset in DEFUSE 3. Background and Purpose- Efficacy of endovascular thrombectomy has been demonstrated up to 24 hours after stroke onset in patients selected with perfusion imaging. We hypothesized that a persistent favorable perfusion profile exists in some patients beyond 24 hours from the onset and can be predicted by a lower baseline hypoperfusion intensity ratio, which indicates favorable collaterals. Methods- We identified

Full Text available with Trip Pro

2019 Stroke Controlled trial quality: uncertain

14. Clinical Practice Guideline for the Treatment of Intrinsic Circadian Rhythm Sleep-Wake Disorders: Advanced Sleep-Wake Phase Disorder (ASWPD), Delayed Sleep-Wake Phase Disorder (DSWPD), Non-24-Hour Sleep Wake Rhythm Disorder (N24SWD), and Irregular Sleep-W

Clinical Practice Guideline for the Treatment of Intrinsic Circadian Rhythm Sleep-Wake Disorders: Advanced Sleep-Wake Phase Disorder (ASWPD), Delayed Sleep-Wake Phase Disorder (DSWPD), Non-24-Hour Sleep Wake Rhythm Disorder (N24SWD), and Irregular Sleep-W JCSM - Clinical Practice Guideline for the Treatment of Intrinsic Circadian Rhythm Sleep-Wake Disorders: Advanced Sleep-Wake Phase Disorder (ASWPD), Delayed Sleep-Wake Phase Disorder (DSWPD), Non-24-Hour Sleep-Wake Rhythm Disorder (N24SWD (...) -Wake Phase Disorder (ASWPD), Delayed Sleep-Wake Phase Disorder (DSWPD), Non-24-Hour Sleep-Wake Rhythm Disorder (N24SWD), and Irregular Sleep-Wake Rhythm Disorder (ISWRD). An Update for 2015 R. Robert Auger, MD 1 ; Helen J. Burgess, PhD 2 ; Jonathan S. Emens, MD 3 ; Ludmila V. Deriy, PhD 4 ; Sherene M. Thomas, PhD 4 ; Katherine M. Sharkey, MD, PhD 5 1 Mayo Center for Sleep Medicine, Rochester, MN; 2 Rush University Medical Center, Chicago, IL; 3 Portland VA Medical Center, Portland, OR; 4 American

2015 American Academy of Sleep Medicine

15. Fingolimod enhances the efficacy of delayed alteplase administration in acute ischemic stroke by promoting anterograde reperfusion and retrograde collateral flow. (PubMed)

Fingolimod enhances the efficacy of delayed alteplase administration in acute ischemic stroke by promoting anterograde reperfusion and retrograde collateral flow. The present study was undertaken to determine the efficacy of coadministration of fingolimod with alteplase in acute ischemic stroke patients in a delayed time window.This was a prospective, randomized, open-label, blinded endpoint clinical trial, enrolling patients with internal carotid artery or middle cerebral artery proximal (...) occlusion within 4.5 to 6 hours from symptom onset. Patients were randomly assigned to receive alteplase alone or alteplase with fingolimod. All patients underwent pretreatment and 24-hour noncontrast computed tomography (CT)/perfusion CT/CT angiography. The coprimary endpoints were the decrease of National Institutes of Health Stroke Scale scores over 24 hours and the favorable shift of modified Rankin Scale score (mRS) distribution at day 90. Exploratory outcomes included vessel recanalization

2018 Annals of Neurology Controlled trial quality: uncertain

16. Fingolimod Enhances the Efficacy of Delayed Alteplase Administration in Acute Ischemic Stroke by Promoting Anterograde Reperfusion and Retrograde Collateral Flow. (PubMed)

Fingolimod Enhances the Efficacy of Delayed Alteplase Administration in Acute Ischemic Stroke by Promoting Anterograde Reperfusion and Retrograde Collateral Flow. The present study was undertaken to determine the efficacy of coadministration of fingolimod with alteplase in acute ischemic stroke patients in a delayed time window.This was a prospective, randomized, open-label, blinded endpoint clinical trial, enrolling patients with internal carotid artery or middle cerebral artery proximal (...) occlusion within 4.5 to 6 hours from symptom onset. Patients were randomly assigned to receive alteplase alone or alteplase with fingolimod. All patients underwent pretreatment and 24-hour noncontrast computed tomography (CT)/perfusion CT/CT angiography. The coprimary endpoints were the decrease of National Institutes of Health Stroke Scale scores over 24 hours and the favorable shift of modified Rankin Scale score (mRS) distribution at day 90. Exploratory outcomes included vessel recanalization

2018 Annals of Neurology Controlled trial quality: uncertain

17. Developing a Management Approach for Patients With "Late-Onset" Pompe Disease

features may go unrecognized in childhood without vigilant clinical examination and assessments with appropriate functional tests. In our clinical experience, children with the "late-onset" GAA variant may present much earlier in life and adult patients with LOPD consistently report a much earlier symptom onset and a significant diagnostic delay. These patients have shown improvement after initiation of ERT but have motor impairments adversely affecting their quality of life and growth from early (...) and 12 month visit. The study has three goals: To study and record disease specific clinical symptoms in newborns and infants with Pompe disease without cardiomyopathy (disease of the heart muscle) identified through newborn screening (NBS) To devise an approach to characterize early musculoskeletal (muscles and joints) involvement in subjects with the "late-onset" GAA variant identified by NBS To determine criteria to start preventative therapies including enzyme replacement therapy (ERT

2018 Clinical Trials

18. Early onset complete ovarian failure and lack of puberty in a woman with mutated estrogen receptor beta (ESR2). (PubMed)

Early onset complete ovarian failure and lack of puberty in a woman with mutated estrogen receptor beta (ESR2). Estrogen resistance due to mutations in the estrogen receptor α gene (ESR1) has been described in men and women and is characterized by osteoporosis, delayed bone age and continuous growth in adulthood, and delayed puberty and multiple ovarian cysts in women. Although mutations in the estrogen receptor β gene ESR2 were found in 46, XY patients with differences of sex development (...) in a young woman with complete ovarian failure, suggesting that ESR2 is necessary for human ovarian determination and/or maintenance and that ESR1 is not sufficient to sustain ovarian function in humans.

2018 Journal of Clinical Endocrinology and Metabolism

19. Constitutional Growth Delay (Diagnosis)

growth delay begins to drift further from the growth curve because of delay in the onset of the pubertal growth spurt. Catch-up growth, onset of puberty, and pubertal growth spurt occur later than average, resulting in normal adult stature and sexual development. However, a report by Rohani et al on males with constitutional growth delay—mean age 15.2 years at presentation and 20 years at study’s end—found that the majority of patients attained neither their target height nor their predicted adult (...) of psychosocial problems; nonreferred children with short stature do not differ from those with more normal stature in school performance or socialization. Next: Pathophysiology Constitutional growth delay is a global delay in development that affects every organ system. Delays in growth and sexual development are quantified by skeletal age, which is determined from bone age radiographic studies of the left hand and wrist. Growth and development are appropriate for an individual's biologic age (skeletal age

2014 eMedicine Pediatrics

20. Constitutional Growth Delay (Overview)

growth delay begins to drift further from the growth curve because of delay in the onset of the pubertal growth spurt. Catch-up growth, onset of puberty, and pubertal growth spurt occur later than average, resulting in normal adult stature and sexual development. However, a report by Rohani et al on males with constitutional growth delay—mean age 15.2 years at presentation and 20 years at study’s end—found that the majority of patients attained neither their target height nor their predicted adult (...) of psychosocial problems; nonreferred children with short stature do not differ from those with more normal stature in school performance or socialization. Next: Pathophysiology Constitutional growth delay is a global delay in development that affects every organ system. Delays in growth and sexual development are quantified by skeletal age, which is determined from bone age radiographic studies of the left hand and wrist. Growth and development are appropriate for an individual's biologic age (skeletal age

2014 eMedicine Pediatrics

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>